• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, October 13, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

WVU researchers map crystals to advance treatments for stroke, diabetes, dementia

Bioengineer by Bioengineer
July 3, 2019
in Chemistry
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

MORGANTOWN, W.Va.–Medications attach to the proteins in our bodies the way spacecrafts dock into the International Space Station. Describing that process in detail can reveal a lot about how the medications work–and what form new medications should take.

Researchers at West Virginia University have mapped the crystal structure of a protein that resides in our cells and determined–for the first time–how a drug latches onto it. The findings appear in Communications Chemistry, a Nature research journal.

The study–funded by the West Virginia Clinical and Translational Science Institute–centered on a protein called “mitoNEET.” MitoNEET inhabits the outer membrane of our mitochondria, which act like power plants that energize our cells.

“MitoNEET is a novel therapeutic target for metabolic-based diseases and could possibly lead to disease-modifying treatments for Alzheimer’s disease and stroke,” said Werner Geldenhuys, an associate professor in the School of Pharmacy and School of Medicine. He and his colleagues–including Aaron Robart, an assistant professor in the WVU School of Medicine, John Hollander, assistant dean for professional programs in the WVU School of Medicine, and Timothy Long, an associate professor in the Marshall University School of Pharmacy–carried out the project.

“This protein has been implicated in a lot of diseases that are very tough to tackle: things like diabetes, stroke, heart disease,” Robart said. “We don’t actually know what the protein does yet, but it hangs out in proximity to the powerhouse of the cell, and all of these diseases have an energy-flow theme to them.”

To explore the role mitoNEET plays in our energy processes, the researchers isolated mitoNEET from both bacterial overexpression and animal models. Then they synthesized 11 molecules similar to furosemide–a common diuretic sold under the brand name LASIX–and exposed the mitoNEET to them.

After the molecules bonded to the mitoNEET, the researchers built atom-by-atom maps of the pairings. They remotely controlled Argonne National Laboratory’s Advanced Photon Source–which bombards samples with ultra-bright, high-energy X-rays–to reveal precisely how the molecules came together.

The team discovered that the molecules docked into a cluster of iron and sulfur atoms that made up part of the protein. Raisa Nuñez, an undergraduate participating in the Research Apprenticeship Program, collected preliminary structural data. “This highlights that significant scientific discovery can come at any career level,” Robart said.

“These findings are of importance as they allow us to continue to understand the role played by mitochondria and bioenergetics in many disease states,” Hollander said. “The modulation of mitochondrial function through targeted therapeutics may be a critical avenue of drug discovery.”

Understanding mitoNEET’s cellular function could improve the performance of drugs that work by altering the protein’s activity. For example, adding an extra oxygen group to a drug’s molecular structure could dramatically tighten its bond to mitoNEET and eliminate unintended binding to other cellular proteins.

The potential upshot for patients who take the drug? Better symptom relief.

“The success of this project really illustrates how approaches that are considered basic science can provide considerable insight into clinical problems,” said Michael Schaller, who chairs the School of Medicine’s Department of Biochemistry. “It also demonstrates the power of tackling problems as teams consisting of members with very different expertise.”

###

Research reported in this publication was supported by the West Virginia Clinical and Translational Science Institute. WVCTSI is funded by an IDeA Clinical and Translational grant from the National Institute of General Medical Sciences, under Award Number U54GM104942, to support the mission of building clinical and translational research infrastructure and capacity to impact health disparities in West Virginia.

Citation

Title: Crystal structure of the mitochondrial protein mitoNEET bound to a benze-sulfonide ligand

DOI:

https://doi.org/10.1038/s42004-019-0172-x

Link: https://www.nature.com/articles/s42004-019-0172-x

Check http://wvutoday.wvu.edu/ daily for the latest news from the University.

Follow @WVUToday on Twitter.

Media Contact
Cassie Thomas
[email protected]

Related Journal Article

http://wvutoday.wvu.edu/stories/2019/07/03/wvu-researchers-map-crystals-to-advance-treatments-for-stroke-diabetes-dementia
http://dx.doi.org/10.1038/s42004-019-0172-x

Tags: BiochemistryChemistry/Physics/Materials SciencesMedicine/HealthPharmaceutical Science
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Scientists Unveil Novel Method to Manipulate Mechanical Vibrations in Metamaterials

October 13, 2025
Innovative Chemobiological Platform Converts Renewable Sugars into Key Aromatic Hydrocarbons Found in Petroleum

Innovative Chemobiological Platform Converts Renewable Sugars into Key Aromatic Hydrocarbons Found in Petroleum

October 12, 2025

Harnessing Microwaves to Boost Energy Efficiency in Chemical Reactions

October 10, 2025

Wirth Named Fellow of the American Physical Society

October 10, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1234 shares
    Share 493 Tweet 308
  • New Study Reveals the Science Behind Exercise and Weight Loss

    104 shares
    Share 42 Tweet 26
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    101 shares
    Share 40 Tweet 25
  • Revolutionizing Optimization: Deep Learning for Complex Systems

    91 shares
    Share 36 Tweet 23

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

HERC2: A Promising Biomarker in Ovarian Cancer

Enhancing Multiple Sclerosis Care in Older Adults

2024 European Hypertension Guidelines: Key Recommendations Unveiled

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 64 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.